Petra Laeis

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Pascal Vranckx, Marco Valgimigli, Lars Eckardt et al. · The Lancet · 2019 · 659 citations

Medicine, Cardiology, Pharmacology +16

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction

Petra Laeis, Kurt Püchler, Wilhelm Kirch · Journal of Hypertension · 2001 · 156 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Original Research: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study

Klaus O. Stumpe, Enrico Agabiti‐Rosei, Tomasz Zieliński et al. · Therapeutic Advances in Cardiovascular Disease · 2007 · 110 citations

Medicine, Cardiology, Pharmacology +16

The management of acute venous thromboembolism in clinical practice

Alexander T. Cohen, Anselm K. Gitt, Rupert Bauersachs et al. · Thrombosis and Haemostasis · 2017 · 84 citations · Full text

Medicine, Hematology, Internal Medicine +14

Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil

Klaus von Bergmann, Petra Laeis, Kurt Püchler et al. · Journal of Hypertension · 2001 · 69 citations

Pharmacy, Pharmacokinetics, Pharmacology +16